—
C+
C+ The full Closelook — membership. Open the C+ overview

BridgeBio Pharma Inc (BBIO) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — BridgeBio Pharma Inc

BBIO in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
BridgeBio Pharma develops medicines for genetic diseases. It sells Attruby, an oral stabiliser for transthyretin-mediated cardiomyopathy, and Fosdenopterin under the NULIBRY brand for molybdenum cofactor deficiency. Several other drugs sit in Phase 3 trials, including treatments for achondroplasia, a calcium-related hormonal disorder and a muscular condition, alongside an early-stage gene therapy for Canavan disease. It works through licensing deals with larger pharmaceutical partners. It is based in Palo Alto, California.
Where it sits in the stack
BridgeBio Pharma has no seat in our index; it sits in the Healthcare sleeve of the diary's US universe, grouped there by sector and country rather than by any AI build-out layer.
Who it is priced against
Closelook's peer group here is scored Healthcare names based in the US, among them argenx, Medpace, BeiGene, Regeneron, Vertex and Corcept Therapeutics; the market also names Alnylam Pharmaceuticals as a comparison in genetic-disease drug development.
Why Closelook tracks it
BridgeBio Pharma carries a Closelook score, with momentum the strongest module and valuation the weakest; it holds no index seat and the diary has not yet quoted it.
What the diary watches
Whether the Phase 3 programmes for achondroplasia, the hormonal disorder and the muscular condition report results, since trial outcomes would reset the momentum reading.

BridgeBio Pharma Inc (BBIO) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 34/100 composite (momentum 43, quality 20, valuation 6) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for BBIO, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: price target by Mizuho, 2026-09-01

The Street on this name

Analyst actions and the latest print for BBIO from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Mizuho — target 110 from 96 Target raised to $110 from $96 (+43.6% to spot) 2026-09-01

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against BBIO on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months · buybacks 48 m USD in FY2025

Dividends and capital return

What BBIO pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 48 m USD 0.4% of today's market value
  • Share count +6.0% in FY2025 133 m USD of stock-based compensation in the year
  • Capital returned 48 m USD in a year of negative free cash flow dividends and buybacks together

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 66/100 · S&P 500 fund at 64, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-22
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +10.8% over 20 sessions. Factor regime → 2026-09-22
  • Sector × region Health care in US: +1.7% week · −2.3% month · +12.1% quarter · +12.6% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-22
  • Sovereign pressure Index -0.03 · down 0.40 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-22

FAQ · from the current data · as of 2026-09-23

Quick answers

What is BridgeBio Pharma Inc (BBIO)?

BridgeBio Pharma Inc trades as BBIO on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-23.

Is BBIO in a Closelook index?

Not currently — BridgeBio Pharma Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-23.

What is BridgeBio Pharma Inc's Closelook composite score?

34 out of 100, with momentum 43, quality 20 and valuation 6 sub-scores, as of 2026-09-23. Scores are Closelook's own research readings, not ratings or investment advice.

Where does BBIO trade against its moving averages?

Mixed moving-average stack: Trades -12.2% vs the 50-day and -6.3% vs the 200-day average, 25.9% below the 52-week high and +41.9% off the 52-week low. Computed from daily closes. As of 2026-09-22 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does BridgeBio Pharma Inc do?

BridgeBio Pharma develops medicines for genetic diseases. It sells Attruby, an oral stabiliser for transthyretin-mediated cardiomyopathy, and Fosdenopterin under the NULIBRY brand for molybdenum cofactor deficiency. Several other drugs sit in Phase 3 trials, including treatments for achondroplasia, a calcium-related hormonal disorder and a muscular condition, alongside an early-stage gene therapy for Canavan disease. Closelook's peer group here is scored Healthcare names based in the US, among them argenx, Medpace, BeiGene, Regeneron, Vertex and Corcept Therapeutics; the market also names Alnylam Pharmaceuticals as a comparison in genetic-disease drug development.

Where does BridgeBio Pharma Inc sit in the AI build-out?

BridgeBio Pharma has no seat in our index; it sits in the Healthcare sleeve of the diary's US universe, grouped there by sector and country rather than by any AI build-out layer. BridgeBio Pharma carries a Closelook score, with momentum the strongest module and valuation the weakest; it holds no index seat and the diary has not yet quoted it.

Does BridgeBio Pharma Inc pay a dividend?

No cash distribution shows in BridgeBio Pharma Inc’s price series over the last three years. In fiscal 2025 the company bought back 48 m USD of its own shares. The share count rose 6.0% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on BridgeBio Pharma Inc recently?

The most recent analyst action on BridgeBio Pharma Inc on the Closelook wire is a price target by Mizuho on 2026-09-01 (target 110 from 96). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for BBIO, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.